Nature Communications (Aug 2020)
Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
- Julia Boshuizen,
- David W. Vredevoogd,
- Oscar Krijgsman,
- Maarten A. Ligtenberg,
- Stephanie Blankenstein,
- Beaunelle de Bruijn,
- Dennie T. Frederick,
- Juliana C. N. Kenski,
- Mara Parren,
- Marieke Brüggemann,
- Max F. Madu,
- Elisa A. Rozeman,
- Ji-Ying Song,
- Hugo M. Horlings,
- Christian U. Blank,
- Alexander C. J. van Akkooi,
- Keith T. Flaherty,
- Genevieve M. Boland,
- Daniel S. Peeper
Affiliations
- Julia Boshuizen
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- David W. Vredevoogd
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Oscar Krijgsman
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Maarten A. Ligtenberg
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Stephanie Blankenstein
- Division of Surgical Oncology, The Netherlands Cancer Institute
- Beaunelle de Bruijn
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Dennie T. Frederick
- Department of Surgical Oncology, Massachusetts General Hospital
- Juliana C. N. Kenski
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Mara Parren
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Marieke Brüggemann
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Max F. Madu
- Division of Surgical Oncology, The Netherlands Cancer Institute
- Elisa A. Rozeman
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Ji-Ying Song
- Division of Animal Pathology, The Netherlands Cancer Institute
- Hugo M. Horlings
- Division of Pathology, The Netherlands Cancer Institute
- Christian U. Blank
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- Alexander C. J. van Akkooi
- Division of Surgical Oncology, The Netherlands Cancer Institute
- Keith T. Flaherty
- Department of Medical Oncology, Massachusetts General Hospital
- Genevieve M. Boland
- Department of Surgical Oncology, Massachusetts General Hospital
- Daniel S. Peeper
- Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-020-17739-8
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 13
Abstract
Dedifferentiation state has been associated with therapy resistance in melanoma. Here, the authors uncover a pre-existing NGFR-expressing, targetable subpopulation that is resistant to immunotherapy and other treatments in melanoma cells and preclinical models.
